Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by India Globalization Capital, Inc.

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Announces Results of its 2022 Annual Stockholders Meeting
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for the Quarter Ended June 30, 2022
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for the December 31, 2021 Quarter
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer’s Patients
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for the September 30, 2021 Quarter
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Announces Results of its 2021 Annual Stockholders Meeting
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for the June 30, 2021, Quarter
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer’s Patients
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
From India Globalization Capital, Inc.
Via Business Wire
Tickers IGC
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.